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Abstract Glioblastoma is a rapidly evolving high-grade astrocytoma that is distin-
guished pathologically from lower grade gliomas by the presence of necrosis and
microvascular hyperplasia. Necrotic areas are typically surrounded by hypercellu-
lar regions known as “pseudopalisades” originated by local tumor vessel occlusions
that induce collective cellular migration events. This leads to the formation of waves
of tumor cells actively migrating away from central hypoxia. We present a mathe-
matical model that incorporates the interplay among two tumor cell phenotypes, a
necrotic core and the oxygen distribution. Our simulations reveal the formation of
a traveling wave of tumor cells that reproduces the observed histologic patterns of
pseudopalisades. Additional simulations of the model equations show that prevent-
ing the collapse of tumor microvessels leads to slower glioma invasion, a fact that
might be exploited for therapeutic purposes.
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1 Introduction
Malignant gliomas are the most common and lethal type of primary brain tumor.
Survival for patients with glioblastoma multiforme (GBM), the most aggressive
WHO grade IV astrocytic glioma (Louis et al. 2007; Wen and Kesari 2008), is
about 14 months after diagnosis, using surgery, radiotherapy, and chemotherapy
(temozolamide) (Huse and Holland 2010; Van Meir et al. 2010; Clarke et al. 2010;
Reardon et al. 2011; Pruitt 2011). GBM periphery typically shows tumor cells infil-
trating into the normal brain which often invade the adjacent cortex and the contralat-
eral hemisphere. Indeed, migrating cells which are not eliminated by surgical resec-
tion will cause the tumor to recur in the interim of 3–6 months (Onishi et al. 2011;
Giese et al. 2003).
GBMs are heterogeneous, but are distinguished pathologically from lower grade
gliomas by the presence of hypervascularized areas under moderate levels of hypoxia
(deficit in oxygenation) and central necrosis usually surrounded by hypercellular re-
gions known as pseudopalisades (Gorin et al. 2004). Examples of these hypercellular
perinecrotic structures are shown in Fig. 1.
Hypoxia is a feature encountered in most solid tumors (Semenza 2009; Vaupel
2008; Bristow and Hill 2008; Dewhirst et al. 2008). Albeit its incidence and severity
varies among patients, it is recognized as a negative clinical prognostic and predictive
factor owing to its involvement in various cancer hallmarks (Hanahan and Weinberg
2011; Wilson and Hay 2011) and displays a central role in tumor progression and
therapy resistance, especially in GBM (Jensen 2009; Pope et al. 2011). Hypoxia is
observed both in the near vicinity of the tumor vasculature (Bristow and Hill 2008;
Dewhirst et al. 2008) and at longer distances of about 150 µm from the vessels (Bris-
tow and Hill 2008). Angiogenesis emerges then in response to the proangiogenic
growth factors imbalance driven by hypoxic tumor cells such as vascular endothelial
growth factor (VEGF) relative to anti-angiogenic growth factors (e.g., angiostatin)
(Carmeliet and Jain 2011; Ebos and Kerbel 2011). Although GBM is one of the high-
est vascularized human tumors, its microcirculation is very inefficient (Jensen 2009)
with parenchymal edema and poor maintenance of the blood brain barrier (Jain et al.
2007) leading to a decrease in oxygen and nutrients supply and debris removal. Mi-
crovascular hyperplasia, which is a form of angiogenesis morphologically recognized
as endothelial proliferation within newly sprouted vessels, is spatially and temporally
associated with pseudopalisading necrosis and is believed to be driven by VEGF
(Rong et al. 2006).
Experimental studies have hypothesized that pseudopalisade formation could ex-
plain the rapid clinical progression of GBM. In fact, it may act as a link among the
underlying vascular damage, the development of hypoxia and the hypoxia-induced
angiogenesis, leading to necrosis and accelerated outward tumor expansion by a mi-
grating wave of cells. An intriguing observation was that proliferation rates were
lower in pseudopalisades than in adjacent astrocytoma for nine different glioma lines
(Brat et al. 2004). Since pseudopalisades are mainly composed of hypoxic cells, there
exists biological evidence to think that hypoxic cells proliferation indices are lower
than normoxic ones and that cell proliferation is not the cause of pseudopalisades
formation.
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Fig. 1 Pseudopalisades in histopathological samples of GBM. (A) Hypercellular regions appear around
centrally occluded vessels (star). The standard interpretation (Brat et al. 2004) is that cells migrate away
from the degenerated vessels (hypoxic areas) and move toward functional vessels (arrow). (B) Necrosis
formation and the emergence of pseudopalisades is part of a crucial multistep process for the accelerated
progression of high grade astrocytic gliomas. The development of an envelope of small scale pseudopal-
isades may play a relevant role in the global migratory dynamics and invasion of these malignant gliomas
driven by vaso-occlusive events occurring at the small cellular scale, leading to the distinctive feature in
GBM (Brat et al. 2004). Scale bars are 100 and 300 µm, respectively
Previous works have proposed pseudopalisade formation as a multistep process
(Brat et al. 2004; Rong et al. 2006; Brat and Van Meir 2004): First, tumor cells
proliferate and infiltrate through the parenchyma and receive oxygen and nutrients
via the intact native blood vessels. Secondly, uncontrolled tumor growth and proco-
agulant factors expression cause endothelial injury and vascular leakiness resulting
in intravascular thrombosis which increase hypoxia in the regions surrounding the
vessel (Rahman et al. 2010). Subsequently, tumor cells begin to migrate away from
hypoxia, creating a peripherally moving wave that is seen microscopically as pseu-
dopalisading cells, leading to an expansion of the hypoxia zone and central necrosis
(see Fig. 1(A)). Meanwhile, hypoxic pseudopalisades tumor cells secrete proangio-
genic factors giving rise to more aberrant vessels that will again eventually suffer
vaso-occlusions.
In this work, we model the hypercellular regions formation in GBMs perinecrotic
areas including the spatiotemporal interplay among normoxic and hypoxic tumor
cell, a necrotic core, and the oxygen distribution. Our physio-pathologic scenario
is depicted in Fig. 2, and consists of a tumor cell population embedded within two
blood vessels arranged in a line domain. Our numerical simulations reveal the forma-
tion of a superimposed traveling wave of hypoxic cells that qualitatively reproduces
the experimentally observed patterns and provide an estimate of palisade timescale
formation, lifetime, and persistence among other prognostic metrics. We also ex-
plore the dynamics of tumor spreading under delayed vascular injury and show
that somehow, in the framework of our model, preventing vessels from breaking
leads to slower tumor invasion speeds that might be explored for therapeutic pur-
poses.
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Fig. 2 GBM microenvironment model. The system modeled here consists of two blood vessels and an
evolving embedded population of tumor cells whose phenotype changes according to the oxygen level.
Upon thrombosis of one of the blood vessels (the right one), due to excessive tumor cell growth and the
secretion of thrombotic factors, local oxygen decreases promoting a massive migration of hypoxic glioma
cells (labeled as II) toward better oxygenated areas. In the process, hypoxic glioma cells infiltrate among
the normoxic glioma cells (labeled as I), which are closer to a functional vessel (the left one), creating a
transient hypercellularity region (a pseudopalisade). As the pseudopalisading front of glioma cells enlarges
around the thrombosed vessel, perivascular necrosis becomes more prominent
2 The Model
2.1 Glioblastoma Compartment Dynamics
GBM is the most heterogeneous primary brain tumor. Studies by Anderson et al.
(2009), using three different discrete models, have shown that when low oxygen
switch occurs, a large percentage of the populations become growth arrested or re-
moved and the remaining cells are mainly dominated by a single aggressive phe-
notype. One could include a large range of phenotypes, but such a complex model
would involve many unknown parameters.
Actually, a single-cell based model would allow us, in principle, to follow the
individual movement of the transformed astrocytes through the brain parenchyma.
However, considering that the basic rules behind a model are more important than
model details, we discarded both the use of on-lattice models, which are not realistic
when cell motion is considered, and off-lattice models, which assume unrealistic cell
geometries and/or incorporate unknown cell-cell interactions. Besides, these models
often need a large number of unknown parameters and require initial cell configura-
tion which are extremely difficult to validate in in vivo experiments. Thus, since any
discrete model will also miss relevant details, we have opted for a continuous model,
which does not show any strong spatial localization effects in our simulations.
It is believed that glioma cells follow the migration/proliferation dichotomy (Giese
et al. 2003) where highly motile cells exhibit low proliferation rates. The prolifera-
tive to invasive switch phenotype cannot be only mutation driven (Onishi et al. 2011;
Hatzikirou et al. 2012) and it has been suggested that invasive glioma cells are able
to revert to a proliferative program and vice versa, depending on environmental stim-
ulies (Giese et al. 2003; Keunen et al. 2011) such as the oxygen which may drive
the transformation. Thus, for each oxygen level, there exists a dominant (fittest) tu-
mor cell phenotype corresponding to certain ratio proliferation/migration rates (Giese
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et al. 2003). In an in silico study, Anderson et al. (2009) studied the evolution of 100
phenotypes with different aggressiveness concluding that the competition between
cells induced by oxygenation selects the invasive tumor cell phenotype.
Our modeled system comprises three different compartments: two different cou-
pled tumor cell subpopulations, competing for space and resources (oxygen), corre-
sponding to the two dominant phenotypes, normoxic Cn and hypoxic Ch, well de-
scribed in GBM (DeBerardinis et al. 2007; Giese et al. 2003; Keunen et al. 2011;
Onishi et al. 2011). Of the two populations, the first one, Cn, consists of normoxic,
proliferative, less mobile cells (typically located close to functional blood vessels),
whereas the second one, Ch, is composed of hypoxic, less proliferative, and more
mobile cells. The cell loss is included in a third compartment, Cd , of necrotic tissue.
The equations governing the interplay among these three densities are as follows:
∂Cn
∂t
= Dn∇2Cn + 1
τn
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= Dh∇2Ch + 1
τh
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The first terms in Eqs. (1a) and (1b) account for cellular motility. Here, we assume,
as in most models (Frieboes et al. 2007; Swanson et al. 2008; Bondiau et al. 2008;
Eikenberry and Kuang 2009; Konukoglu et al. 2010; Rockne et al. 2010; Pérez-García
et al. 2011) that glioma cell invasion throughout the brain is governed by a standard
Fickian diffusion process. Since the hypoxic phenotype is more migratory than the
normoxic one (Berens and Giese 1999; Giese et al. 2003; Bristow and Hill 2008;
Gorin et al. 2004), hypoxic cell diffusion coefficient Dh is larger than the normoxic
one Dn.
The second terms in Eqs. (1a) and (1b) employ a classical logistic growth for
the tumor cell populations with proliferation times τn and τh, respectively, and a
maximum density capacity C(M). Since normoxic cells are more proliferative than
hypoxic ones, then τn < τh. Growth is assumed to be space-limited.
The third and forth terms in Eqs. (1a) and (1b) represent the phenotypic switch-
ing functions Sij (see Fig. 3), which are step-like oxygen-dependent functions. Un-
der low oxygenation (below O(S)2 ), normoxic cells change to the hypoxic phenotype
(Snh) with a characteristic time τnh due to the hypoxia-inducible factor 1α (HIF-1α)
accumulation and the glycolytic and angiogenesis mechanisms initiate (Jewell and
Gassmann 2001). Similarly, when oxygenation is sufficient (above O(S)2 ), hypoxic
cells recover their oxic phenotype, (Shn) with a characteristic time τhn. However, hy-
poxic cells suffering persistent anoxia (below O(D)2 ) start to die (Shd ) in Eq. (1c) with
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Fig. 3 Oxygenation levels influence tumor cell phenotype. Oxygenation drives the phenotypic switching
mechanisms coupling the populations: Normoxic to hypoxic, Snh , hypoxic to normoxic Shn and hypoxic
to necrotic Shd . High oxygen levels favor the existence of more proliferative phenotypes which are less
mobile. On the contrary, cells respond to low oxygen concentrations by expressing less proliferative phe-
notypes, which are more motile. Finally, hypoxic cells experiencing persistent anoxia eventually die (Brat
et al. 2004)
a characteristic time τhd . The parameter O2 accounts for the characteristic width
where the transitions occur around the critical values O(S)2 and O
(D)
2 .
Glioma cell loss occurs both by a controlled suicide (apoptosis) and by an uncon-
trolled damage due to extremely unfavorable conditions (necrosis) (Hotchkiss et al.
2009). On the one hand, apoptosis does not correlate with prognosis (Migheli et al.
1994; Schiffer et al. 1995), does not lead to the fill up of space and can be simply
incorporated into effective proliferation cell rates in Eqs. (1a) and (1b). On the other
hand, necrosis represents a massive cell death and its degree is inversely related to
patient survival (Nelson 1983 and Lacroix et al. 2001). Since it happens at a different
rate and occupies space, we incorporate Cd into the proliferation limiting terms in
Eqs. (1a) and (1b).
2.2 Microenvironment Oxygenation
Though the GBM microenvironment is highly heterogeneous (Bonavia et al. 2011),
two of the main chemical agents implicated in its growth are oxygen and nutri-
ents, mainly glucose and lactate (Mendoza et al. 2011; Griguer et al. 2005, 2008;
Seyfried et al. 2011). Here, we show that it suffices to take oxygen as the key
agent driving the collective cell migration dynamics to understand pseudopalisade
formation. Moreover, glucose is less scarce than oxygen and can be replaced by
other fuels (Beckner et al. 2005; DeBerardinis et al. 2007; Grillon et al. 2011;
Mendoza et al. 2011).
Oxygen heterogeneities are very relevant in gliomas and in other tumors (Evans
et al. 2004). The spatiotemporal oxygen variation, driving the presence of various
phenotypic tumor subpopulations, would help to explain the diversity of responses
obtained from the same treatment. Here, a Michaelis–Menten type kinetics is used for
the oxygen uptake (Patel et al. 2001; Ferreira et al. 2002) encompassing the feedback
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The first term in Eq. (2) accounts for the oxygen diffusion assuming a homogenous
and isotropic diffusion coefficient DO2 for simplicity. Although oxygen passes suc-
cessively through the intracellular fluid, cell membranes and cytoplasm, employing
an average diffusion coefficient has been proven to be a good approximation (Tan-
nock 1972; Pogue et al. 2001). The second term models oxygen uptake by normoxic
and hypoxic cells at rates αn and αh, respectively. The saturation Michaelis–Menten
constant O(T )2 corresponds to the oxygen concentration level at which the reaction
rate is halved.
Although it is possible to incorporate the oxygen supply by resorting to extra
source functions, here oxygen will be provided initially through the two capillaries
located at the tumor boundaries domain and as soon as one of the two blood ves-
sels becomes impaired by a thrombus, the remaining functional one will be the sole
source of oxygen (see Fig. 2).
2.3 Parameter Estimation
A large range of cell phenotypes with different parameters exists, but those with bet-
ter adapted characteristics will be the ones reaching the normoxic region. We re-
sort to mean available experimental values from human glioma models to obtain
order-of-magnitude estimates of the intervening parameters in our equations. First,
the maximum cell density C(M) has been estimated in previous works (see, e.g.,
Rockne et al. 2010) to be about 106 cell/cm2. Oxygen concentration threshold for
hypoxic metabolism is cell line dependent but experimental evidence supports for
glioma the choice of 7 mmHg (Vaupel 2004). The Michaelis–Menten constant has
to be smaller than this parameter yet larger than anoxia threshold, about 0.7 mmHg
(Brown and Wilson 2004). We have chosen it to be 2.5 mmHg (Daçu et al. 2003;
Wilson 2008).
Oxygen normoxic and hypoxic uptake values are those from U251 glioma cells
(Griguer et al. 2008). In Table 1 consumption rates are indicated in Mol/(c s), though
they can be put in mmHg/cm by using the ideal gas law.
Since mean oxygen pressure in arterial blood is around 95 mmHg (Kimura et al.
1996) and venous values are around 30–40 mmHg (Wilson 2008), we will take the
oxygen pressure at our boundary capillaries to be Ovi2 = 60 mmHg.
The oxygen diffusion coefficient is classically known to be around 10−5 cm2/s
(Mueller-Klieser and Sutherland 1984) while the cell diffusion coefficients are not
so readily accessible in vivo. We resort to data from Wang et al. (2009), where the
authors assess the invasive capacity of the dominant phenotype linked to the hy-
poxic one in our model. We will take their median migration rate 29 mm2/year as
our fast diffusion coefficient for hypoxic cells. The used normoxic cell diffusion will
be smaller than the hypoxic one, in our case Dn = 0.1Dh.
The hypoxic-normoxic switch time τhn can be estimated from Hsieh et al. (2010),
where the normalization of the response to hypoxia for U87 glioma cells was be-
tween 48 h and 72 h. However, in real situations, τhn typically increases with the
number of hypoxic cycles experienced by cells until they reach a state of physical
balance with HIF1-α. This sequence of oxygen deprivation episodes drives genetic
alterations in the tumor cells so that HIF1-α is stabilized in their nucleus even under
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Table 1 Values of the biological parameters used into our model equations
Variable Description Value References
C(M) Maximum tumor cell
density










2.5 mmHg Daçu et al. (2003)
O
(D)
2 Oxygen level for
anoxia
0.7 mmHg Brown and Wilson (2004)
O
vi
2 , i = 1,2 Vessel oxygen
concentration
60 mmHg Wilson (2008)
Kimura et al. (1996)
αn Normoxic cell oxygen
consumption
10−17 Mol/(c s) Griguer et al. (2008)
αh Hypoxic cell oxygen
consumption
αn/5 Mol/(c s) Griguer et al. (2008)
Dn Diffusion coefficient
for normoxic cells
6.6 · 10−12 cm2/s Tjia and Moghe (2002)
Wang et al. (2009)
Dh Diffusion coefficient
for hypoxic cells
10 Dn cm2/s Tjia and Moghe (2002)
Wang et al. (2009)
DO2 Oxygen diffusion
coefficient
10−5 cm2/s Mueller-Klieser and
Sutherland (1984)
τnh Phenotype switch time
(normoxic to hypoxic)
1 h Jewell and Gassmann (2001)
τhn Phenotype switch time
(hypoxic to normoxic)
96 h Estimated





24 h Ke et al. (2000)
τh Hypoxic cell doubling
time
48 h Giese et al. (2003)






0.1 cm Mazumdar (1992)
oxic conditions, and thus these cells do not return to their previous normoxic state
and become irreversibly hypoxic (Semenza 2009). In or model, when τhn increases,
pseudopalisade formation is enhanced with a larger number of hypoxic cells. This
is in accordance with the observation that a greater number of pseudopalisades and
hypoxic regions correlates with a higher degree glioma.
Finally, the proliferation parameters can be estimated from typical doubling times
that range from 24 to 48 h for glioma cells in vitro for well oxygenated cells, while
the hypoxic cells doubling times are assumed to be longer. Table 1 summarizes the
typical parameter values employed in our calculations.
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2.4 Computational Details
The model given by Eqs. (1a), (1b), (1c) and (2) describes the cell dynamics in the
bulk of the tumor under variable oxygenation conditions. As such, it can be studied on
any particular geometry either regular or irregular with suitable boundary conditions
and/or oxygen sources. It can also be coupled to detailed models of tumor vasculature
such as those based on phase-field models (Travasso et al. 2011) and/or combined
with oxygen-dependent therapies such as radiotherapy (Jensen 2009; Vaupel 2008;
Wilson and Hay 2011). Here, we wish to elucidate the formation of necrotic areas
and hypercellular regions such as those observed in gliomas. To do so, we will stick
to the simplest possible scenario: one-dimensional tumor sections with blood vessels
located on two opposite boundaries and oxygen flow coming from the end points of
the domain.
Exchange of gases, nutrients, and waste materials occurs through the thin perme-
able walls of the vessels, which in our case, are assumed to be capillaries. We will
denote the oxygen concentration on the two lateral vessels at a given time t by Ov12 (t)
and Ov22 (t). Oxygen flows from vessels to the tissue to balance oxygen pressures.








2 (t) − O2
)
, i = 1,2. (3)
The capillary length in our model simulations is taken to be ≤1 mm to match the real
capillary size (Mazumdar 1992). In addition, oxygen concentration in the capillary
network does not follow the variations induced by the circulation in the major blood
vessels (Daçu et al. 2003). Since our computational domain extends over a small
spatial region (vessels distance lower than 700 µm), we assume that oxygenation is
independent on the position along the capillaries.
Likewise, the oxygen exchange coefficient Ji is considered to be constant and
equal for both vessels, therefore, |J1| = |J2| = J . Bearing in mind that the average
blood velocity for capillaries is around 0.1 cm/s (Mazumdar 1992) we can estimate
its value to be J ∼ 0.1 cm. Notice that oxygen spreads either away from or into the
vessel depending on oxygen pressures.
It is a fact that GBM only rarely metastatizes out of the brain since GBM cells
do not intravasate to the blood vessels (Bellail et al. 2004). Therefore, we impose ho-
mogeneous Neumann boundary conditions for the cell densities to supplement model
equations (1a), (1b), (1c) and (2).
To solve our model equations we have used second order finite differences in space
with an explicit fourth-order Runge–Kutta method in time. Typical parameter values
for the spatial step were x = y = 5 µm, and t = 0.01 s.
In all of the simulations to be presented later, we assume an initial concentration
of normoxic tumor cells in the region limited between two functional vessels. Thus,
initially, the hypoxic and necrotic cell densities are zero for all x ∈ (0,Lx). The ini-
tial oxygen distribution is randomized with 24 mmHg as the mean oxygen partial
pressure, as described by Vaupel et al. (1989). Except when otherwise stated, we
will suppose that the vessel v1 is disrupted at t = 0 so that v2 remains as the only
functional vessel through the simulation.
2884 A. Martínez-González et al.
3 Results
3.1 Vaso Occlusions Trigger Necrosis, Pseudopalisades, and Vessel-Cooption
We have solved our model equations (1a), (1b), (1c) and (2) by including only the
essential cellular biological facts allowing us to understand the palisading necrosis
formation, and to get an insight on their formation as well as estimates of their life-
times and sizes. Once the parameters are chosen in the appropriate realistic ranges
(see Table 1), pseudopalisade formation does not require a detailed parameters fine-
tuning, but it is a characteristic phenomenon arising in many of our simulations as
transient states.
In Fig. 4, we present the results for different cell density evolutions when normoxic
GBM cells are seeded close to one of two vessels located at the boundaries of a
brain tissue slice of length Lx = 300 µm. The initial (normoxic) tumor cell density
surrounds one of the vessels, x ∈ (0,Lx/2] (lower black line of Fig. 4), and is zero for
x ∈ (Lx/2,Lx]. We assume well brain oxygenation until the lower vessel is disrupted
at t = 0 so that, at the outset, the hypoxic and necrotic cell densities are zero in the
whole computational domain.
After thrombus induction by high adjacent cell density, a normoxic to hypoxic
switch, due to oxygen deprivation, leads to an enhanced mobility and reduced pro-
liferation in the perivascular area to find a more nourishing environment to survive
(Fig. 4(A)). A complete phenotypic switch occurs in about 1 hour (see Fig. 4(B))
and hypoxic cells (Fig. 4(C)) increase their flux to the upper vessel (in red) which
still functional, generating a transient traveling wave of hypoxic cells (see Fig. 4(D)
where the arrow shows the movement direction).
Figures 4(E, F) depict the formation of a pseudopalisade in the scale of 1 day that
develops during the subsequent days. A morphologic analysis of Figs. 4(E) and F
gives about 130 µm as their characteristic width. According to Brat et al. (2004), pseu-
dopalisades with small widths have smaller necrotic cores. In our case, the necrotic
core is about 30 µm (Fig. 4(G)) and it is also formed in the same time scale of days.
Nevertheless, there is a significant density of migrating hypoxic cells that reach the
functional vessel. Actually, the total cell number evolution (Fig. 4(H)) shows that hy-
poxic cell number increases significantly fast during the first hours after the thrombus
but then moderates its growth rate. Normoxic cell numbers initially decay and relapse
once the functional vessel has been co-opted. In less than a week, tumor cells invade
the total tissue.
In a second set of simulations, displayed in Fig. 6, we study the invasion of a tumor
vessel by a pseudopalisading wave of hypoxic cells coming from another impaired
vessel. As in the previous case, a high normoxic cell density is seeded around the
lower vessel (see Fig. 6), but now we assume that a small number of normoxic tumor
cells have already migrated to the upper vessel starting to colonize it (400 µm vessels
distance). Initial conditions for the normoxic tumor cell density and oxygenation are
shown in Fig. 5.
The simulation starts when the lower vessel collapses induced again by the adja-
cent high density of proliferating normoxic tumor cells. The upper vessel, fully func-
tional during the simulation, is completely invaded after 7 days by a high tumor cell
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Fig. 4 Spatiotemporal simulations showing the formation of necrotic areas surrounded by hypercel-
lular regions (pseudopalisades). Initially, normoxic GBM cells are seeded close to the lower vessel.
Pseudo color plots in A, B, C, E, and G represent normoxic, normoxic (notice the scale), hypoxic, total
(hypoxic + normoxic) populations and necrotic tissue densities, respectively. The horizontal and vertical
axes correspond to time in days (except for B in hours) and space in µm, respectively. D and F depict the
normoxic and total (normoxic + hypoxic) cell densities as a function of space for specific times indicated
in each curve and also with vertical color lines in C and E. H shows the GBM cell number evolution with
time for the different populations. At t = 0, the lower vessel suffers a thrombus, while the upper vessel
remains fully functional during the simulation. The parameters used in the simulations are listed in Table 1
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Fig. 5 Initial conditions for the simulation in Fig. 6. (A) Normoxic cell density. (B) Initial oxygen distri-
bution with 24 mmHg as the average oxygen pressure for a healthy brain tissue (Vaupel et al. 1989) and
oxygen distribution along the interval of 1, 3, and 7 days after the vessel occlusion in dark blue, green, and
red lines, respectively
density that might induce new vaso occlusions (Fig. 6(A)). Hypoxic cells (Fig. 6(C))
generate a transient traveling wave (Fig. 6(D)) where the arrow shows the movement
direction. Figures 6(E) and (F) show the pseudopalisade formation in one day that
develops during the ensuing 7 days.
A morphologic analysis of Figs. 6(E) and (F) gives about 150 µm as the character-
istic width value. The necrotic core is about 60 µm (Fig. 6(G)) and is also formed in
the same scale of days. Finally, total cell number evolution observed in Fig. 6(H) is
similar to the previous simulation and again normoxic cell numbers have a different
growth pattern than the hypoxic one.
It is important to underscore that this minimal model not only reproduces the
clinical observations seen in immunohistochemical analysis of histologic sections
of GBM samples (Brat et al. 2004), but may also contribute to a better understand-
ing of the origin and evolution of those structures and to find unknown quantities
such as the typical palisade lifetime or the relationship between palisade lifetime/size
and vessel distance. Moreover, the macroscopic progression of GBM can be par-
tially conceived, from a microscopic point of view, as consisting of a large num-
ber of intravascular thrombotic events (caused by unregulated tumor cell prolifera-
tion in the vicinity of the vessels) giving rise to the formation and coalescence of
small necrotic foci coupled with subsequent episodes of hypoxic cell migrations in
search of nearby functional blood vessels, which will eventually suffer new intravas-
cular thrombotic events. The envelope of many of these small-scale pseudopalisades
contributes to the high density regions on larger spatial scales as those shown in
Fig. 1(B).
3.2 Palisading Waves Invade Faster than the Pure Random Motion Waves
In principle, it is not clear how vaso-occlusive events relate to the tumor invasion
speed. GBM features such as hypercoagulation or abnormal angiogenesis may be
linked at the molecular level and hypoxia may coordinate the hypercoagulative ac-
tivity of GBM cells and (protease-activated receptor) PAR-mediated angiogenic sig-
naling (Svensson et al. 2011). To gain further quantitative insight of vaso-occlusive
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Fig. 6 Spatiotemporal simulations showing the formation of perinecrotic pseudopalisades after a va-
so-occlusive event. In contrast with Fig. 4, here both vessels are initially seeded with normoxic GBM
cells. After 7 days, the upper vessel is completely invaded by a high GBM cell density and again a va-
so-occlusion event may occur at any moment. All of the subplots and the rest of parameters are as in Fig. 4
and the initial data for oxygen and tumor cells are shown in Fig. 5
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Fig. 7 Palisading waves invade faster than pure random motion waves. (A–B) Tumor cell densities evolu-
tion along time and space when only the upper vessel is functional while the lower one becomes impaired
at t = 0. Parameters are as in Fig. 4. A depicts the total GBM cell density as a function of time, while B
presents density curves at various times showing the advance of the tumor front. (C–D) Same as in (A–B)
but when both vessels remain functional. All parameters and initial conditions are taken as in Fig. 4
events influence to the tumor progression speeds, we have performed a series of nu-
merical simulations in Fig. 7.
Subplots A, B correspond to the case discussed previously where the upper ves-
sel works normally but the lower becomes impaired due to the thrombus formation
thrombus. On the contrary, subplots C,D show the tumor progression when both ves-
sels remain functional. In the first case, the functional vessel is invaded by the tumor
after 8 days by a high tumor cell density (more than 45 %). However, when no throm-
bus is formed and both vessels stay functional (subplots C and D) invasion becomes
significantly slower; requiring 13.5 days to attain the same tumor cell density around
the upper vessel.
Figure 7 displays the coexistence of two mechanisms driving invasion: one purely
diffusive and similar to that governed by a free growth (when resources are not lim-
ited) obeying the Fisher–Kolmogorov equation, as described by Swanson et al. (2008)
and related works. The second one shows an accelerated invasion caused by micro
thrombi formations in the tumor vessels. Thus, on the basis of our model, it appears
that vaso-occlusive events in GBM may play a key role in accelerating the tumor
invasion process through pseudopalisade formation. This suggests that the use of
chemical agents slowing-down the vessel impair might delay tumor progression in
GBM patients. This fact will be discussed thoroughly in Sect. 4.
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Fig. 8 Occluded-functional vessel distance, palisade width and its lifetime link. In all simulations, GBM
normoxic cells are seeded close to the impaired vessel with a small fraction of them already invading the
functional vessel. Initial conditions are chosen similar to those of Fig. 6 and proportional to the tissue
size. At t = 0, one of the vessels collapses while the second remains functional during the simulated
time window. Characteristic pseudopalisade width and lifetime data are labelled by blue triangles, and red
squares, respectively. Also shown is the dependence of the necrotic core width with the tissue size (green
circles). The horizontal axis represents the blood vessels distance (tissue size) in µm. Vertical axes label
the palisade and the necrotic foci widths in µm (left one); pseudopalisade lifetime in hours (right one). The
parameters used in the simulations are listed in Table 1
3.3 Vessel Distance, Palisade Lifetime and Necrotic Width Relationship
To further substantiate our results, we have carried out a numerical study of the re-
lation between the separation between a thrombotic vessel and another functional
vessel, the palisade width and its lifetime, as depicted in Fig. 8. The characteris-
tic width of the pseudopalisade corresponds to the dimensions of the hypercellular
region and its lifetime is the time elapsed since the palisade is formed until it disap-
pears. Although the standard distances between blood vessels are in the range of 100
to 400 µm, due to the irregular tumor vasculature, we have considered a wider range
(from 50 to 700 µm) assuming that those histologic samples showing distances larger
than 700 µm will have other closer fonts not visible in pathological analyses due to
its spatial arrangement.
In our computational window, the blood vessels distance equals the tissue size and
so when this is smaller than 100 µm the formation of pseudopalisades is practically
nonexistent. Figure 8 shows how the pseudopalisade size depends on vessels distance
(it may be also expected to be roughly proportional to the vessel size), growing in a
linear fashion as the distance increases until it reaches a plateau value close to 200 µm.
Figure 8 shows that if the distance from a thrombotic vessel to the nearest func-
tional vessel is short enough, the cells arrive to better oxygenated areas without ex-
periencing severe hypoxic stresses (thus diminishing their death) and reducing the
palisade lifetime. However, if this distance is larger than 150–200 µm (or if the bro-
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ken vessels are larger), there will be a considerable number of hypoxic cells unable
to escape from severe hypoxia giving rise to larger necrotic areas and longer palisade
lifetimes. The model, although biologically simple and solved on a line domain, sup-
ports the hypothesis that large pseudopalisades are more persistent. This theory is
well based on the pathology fact that pseudopalisades surrounding larger broken ves-
sels are easier to observe (cf. Fig. 8).
4 Impact and Therapeutic Implications
4.1 Impact
It is well known in biological contexts that some aspects of glioma dynamics can
be understood in terms of two cell subpopulations corresponding to two domi-
nant phenotypes (Giese et al. 2003; DeBerardinis et al. 2007; Keunen et al. 2011;
Onishi et al. 2011; Hatzikirou et al. 2012). This means that minimal mathematical
models such as those based on Fisher–Kolmogorov type equations accounting for
GBM progression (Frieboes et al. 2007; Swanson et al. 2008; Bondiau et al. 2008;
Eikenberry and Kuang 2009; Konukoglu et al. 2010; Rockne et al. 2010; Pérez-García
et al. 2011) may benefit from incorporating the two different phenotypes and necrosis
as it is done in this paper. On the other hand, the development of an envelope of small
scale pseudopalisades may play a relevant role in the global migratory dynamics and
invasion of these malignant gliomas driven by vaso-occlusive events occurring at the
small cellular scale, leading to the distinctive GBM feature of showing significant
necrotic areas, as observed in clinical imaging such as the on exhibited in Fig. 1(B).
However, in order to incorporate necrosis not only phenomenologically, as in
Pérez-García et al. (2011), it is necessary to take into account the basic interven-
ing steps involved in palisade formation discussed in Brat et al. (2004) and Brat and
Van Meir (2004). Our simulations show that vascular damage is not only a key event
in the necrosis formation but also a driving force for migration which is linked to the
cell densities evolution.
Other possible extensions regard the presence of a small number of treatment-
resistance (cancer-stem) cells in GBM and whether their metabolism can be effec-
tively targeted. Indeed, determining whether this small fraction mainly depends on
aerobic glycolysis or on oxidative phosphorylation is relevant (Pistollato et al. 2010).
It is known that in glycolytic tumors as GBM, oxidative phosphorylation is not com-
pletely shut down since it provides ATP even under low glucose demand (Vander Hei-
den et al. 2009; Mathupala et al. 2010).
While our distinction of the tumor cell phenotypes has relied on their oxic state, we
anticipate that, among the migratory hypoxic cells seen in pseudopalisades, a small
fraction of them is formed by treatment-resistance cells. Actually, our simulations
suggest that during the time window where hypoxic cells migrate any oxygen de-
pendent treatment will exhibit a poor clinical response (e.g., radiotherapy). Oxygena-
tion importance is further supported by recent experiments by Vlashi et al. (2011) in
which it was observed that in various GBM cell lines, progenitor cells, and those ex-
hibiting a stem-cell-like behavior consume less glucose and produce less lactate while
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maintaining higher ATP levels than their differentiated progeny. They concluded that
GBM stem cells were mostly oxydative. Even from an evolutionary point of view, the
collective migration of hypoxic GBM cells when forming pseudopalisades appears to
be a selection mechanism of the fittest cell phenotypes.
4.2 Therapeutic Implications
Our result that targeting vaso-occlusions might delay GBM tumor progression has
potential therapeutic implications, since increasing the current GBM modest survival
would constitute a big success due to its poor prognosis.
Thromboembolism, (large vessel occlusion), is well recognized as a major cancer
complication and known to be a common cause of death in cancer patients, however,
the contribution of chemotherapeutics, tumor cells, endothelium, and procoagulants
in promoting thrombus continues to be investigated (Khorana and Francis 2008; Furie
and Furie 2006; Zwicker et al. 2007; Green and Kwaan 2009). Specifically, gliomas
have 25 %–30 % of patients sustaining venous thromboembolism (VTE) (Streiff et al.
2004; Simanek et al. 2007) and it is known that glioma cells secrete pro-thrombotic
factors (Bastida et al. 1984) and that the more tumoral tissue is removed the less-likely
are the patients to die from VTE (Brose and Lee 2008; Simanek et al. 2007). This fact
has led to the consideration of thromboprophylaxis for glioma patients with higher
potential risks of VTE (Hamilton et al. 1994; Batchelor and Byrne 2006; Jenkins et al.
2010; Khorana and Francis 2008).
In addition to the VTE prevention there are several direct mechanisms of action
of some anticoagulants, such as low molecular weigh heparine (LMWH), on tumor
cells: direct cell killing (Dos Santos et al. 2010), anti-angiogenic effects (Svensson
et al. 2011) and others (see, e.g., Green and Kwaan 2009, Chap. 15). Our model
results seem to imply that an additional indirect antitumoral effect from thrombopro-
phylaxis might be expected related to the tumor invasion delay, different from the di-
rect antitumoral effect or the VTE prevention. The main limitation in using LMWH
in post-operative patients is the bleeding risk, however, a limited phase II clinical
study of LMWH for high grade glioma patients by Robins et al. (2008) has shown
that it is safe. A phase III trial with a small number of patients seems to confirm this
trend (Perry et al. 2010).
If, as predicted, preventing capillar thrombosis induced by the tumor, results in a
growth tumor delay, a synergistic positive effect with radiation therapy is expected.
Reducing hypoxia would lead to an enhanced tumor radio-sensitivity, that might pro-
vide an extra benefit in survival.
Whether these predictions are clinically relevant remains to be studied, testing
in animal models if LMWH induces a significant reduction of palisade formation
delaying tumor progression and then in clinical trials. Mathematical models might
contribute to design therapies and we expect our work to stimulate theoretical and
experimental studies to follow in this direction.
5 Conclusions
In this work, we have put forward a simple continuous mathematical model allowing
for the description of the formation of hypoxic hypercellular regions around necrotic
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cores in glioblastoma multiform: the so-called pseudopalisades. Pseudopalisading
necrosis and microvascular hyperplasia are two of the most powerful predictors of
poor prognosis among invasive gliomas. These structures could contribute to acceler-
ate growth properties that characterize the low grade to high grade astrocytic glioma
transition.
Our model quantifies the migration process influenced by the cell phenotypic
switch under hypoxic conditions caused by vaso-occlusive episodes. The model ev-
idences that it is possible to observe the dependence between thrombotic-functional
vessel separation, palisade width, lifetime, and its necrotic core. We have also pro-
vided quantitative metrics of the characteristic necrotic core, times of formation, life-
times and width of pseudopalisades after a vaso-occlusion. We stress that these im-
portant metrics are very challenging to measure in vivo because of the small spatial
scale of the phenomena involved and the fact that biopsies do not provide dynami-
cal information in time, but only a fixed. In addition, our results indicate that smaller
pseudopalisades would show shorter lifetimes and reduced necrotic cores while larger
pseudopalisades would display longer lifetimes until reaching a threshold around the
eighth day after the vaso-occlusion. From our calculations, pseudopalisades tend to
present a characteristic width of 200 µm when blood vessel distances are larger than
500 µm (within the range explored up to 700 µm).
Furthermore, our simulations show that palisading waves lead to a faster invasion
than that by a pure random motion invasion with unlimited resources, implying that
the mechanism of vessel break up might accelerate the glioblastoma progression. This
suggests that targeting vaso occlusion events, probably by anticoagulants such as low
molecular weight heparine, might be of potential interest for therapeutics aimed at
delaying glioblastoma growth.
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